Patent: 6,407,103
✉ Email this page to a colleague
Summary for Patent: 6,407,103
Title: | Indeno [1,2-c] pyrazol-4-ones and their uses |
Abstract: | The present invention relates to the synthesis of a new class of indeno[1,2-c]pyrazol-4-ones of formula (I): ##STR1## that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk1-9 and their regulatory subunits know as cyclins A-H. This invention also provides a novel method of treating cancer or other proliferative diseases by administering a therapeutically effective amount of one of these compounds or a pharmaceutically acceptable salt form thereof. Alternatively, one can treat cancer or other proliferative diseases by administering a therapeutically effective combination of one of the compounds of the present invention and one or more other known anti-cancer or anti-proliferative agents. |
Inventor(s): | Nugiel; David A. (Cherry Hill, NJ), Carini; David J. (Wilmington, DE), Di Meo; Susan V. (Wilmington, DE), Yue; Eddy W. (Landenberg, PA) |
Assignee: | Bristol-Myers Squibb Pharma Company (Wilmington, DE) |
Application Number: | 09/731,304 |
Patent Claims: | see list of patent claims |
Details for Patent 6,407,103
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2018-04-21 |
Servier Pharmaceuticals Llc | ONCASPAR | pegaspargase | Injection | 103411 | 02/01/1994 | ⤷ Try a Trial | 2018-04-21 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |